Medtronic FY27 Q1 GAAP diluted EPS rises 40.7% to $1.14; revenue climbs 13.7% to $9.8 billion

• Medtronic Q1 FY27 revenue rose 13.7% to $9.76 billion; GAAP diluted EPS climbed to $1.14.
• GAAP net income attributable to shareholders increased 41.4% to $1.47 billion; GAAP operating profit grew 22.1% to $1.76 billion.
• Cardiovascular revenue increased 19.5% to $3.93 billion; Neuroscience rose 10.3% to $2.68 billion.
• Medical Surgical revenue climbed 10% to $2.28 billion; Diabetes increased 16.9% to $843 million.
• Raised FY27 organic revenue growth outlook to 7.25%-7.75%; lifted diluted non-GAAP EPS view to $5.94-$6.00.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609010645PR_NEWS_USPR_____CG37273) on September 01, 2026, and is solely responsible for the information contained therein.